{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:42:45Z","timestamp":1790037765377,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal antibodies (mAbs) are key components in several therapies for cancer and inflammatory diseases but current knowledge of their clinical pharmacokinetics and distribution in human tissues remains incomplete. Consequently, optimal dosing and scheduling in clinics are affected. With sequential radiolabeled mAb-based imaging, radiation dosing in tissues\/organs can be calculated to provide a better assessment of mAb concentrations in tissues. This is the first pharmacokinetic model of <jats:sup>90<\/jats:sup>Y-Ibritumomab tiuxetan (<jats:sup>90<\/jats:sup>Y-IT) in humans to be described, based on three-dimensional (3D) dosimetry using single-photon emission computed-tomography coupled with computed-tomography. 19 patients with follicular lymphoma were treated initially with <jats:sup>90<\/jats:sup>Y-IT in the FIZZ trial. Based on a compartmental approach individualising the vascular compartment within studied organs, this study proposes a reliable pharmacokinetic (PK) five-compartment model replacing the currently used two-compartment model and constitutes a new direction for further research. This model provides exchange constants between the different tissues, Area Under the Curve of <jats:sup>111<\/jats:sup>In-IT in blood (AUC) and Mean Residence Time (MRT) that have not been reported so far for IT. Finally, the elimination process appears to occur in a compartment other than the liver or the spleen and suggests the metabolism of mAbs may take place mainly on the vascular compartment level.<\/jats:p>","DOI":"10.1038\/s41598-018-33160-0","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T09:46:25Z","timestamp":1538387185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry"],"prefix":"10.1038","volume":"8","author":[{"given":"F.","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dekyndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fulcrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Huglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"D\u00e9caudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-440X","authenticated-orcid":false,"given":"N.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Odou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"33160_CR1","first-page":"4019","volume":"26","author":"M Kuroki","year":"2006","unstructured":"Kuroki, M. et al. Possible applications of antibodies or their genes in cancer therapy. Anticancer Res. 26, 4019\u20134025 (2006).","journal-title":"Anticancer Res."},{"key":"33160_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1568009043332989","volume":"4","author":"V Guillemard","year":"2004","unstructured":"Guillemard, V. & Saragovi, H. U. Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets 4, 313\u2013326 (2004).","journal-title":"Curr. Cancer Drug Targets"},{"key":"33160_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493\u2013507 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"33160_CR4","first-page":"1057","volume":"25","author":"G Paintaud","year":"2009","unstructured":"Paintaud, G. Pharmacokinetics (PK) of mAbs. Med. Sci. MS 25, 1057\u20131062 (2009).","journal-title":"Med. Sci. MS"},{"key":"33160_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","volume":"52","author":"M Dostalek","year":"2013","unstructured":"Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H. & Chetty, M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin. Pharmacokinet. 52, 83\u2013124 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"33160_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.4161\/mabs.29095","volume":"6","author":"JP Davda","year":"2014","unstructured":"Davda, J. P., Dodds, M. G., Gibbs, M. A., Wisdom, W. & Gibbs, J. A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. mAbs 6, 1094\u20131102 (2014).","journal-title":"mAbs"},{"key":"33160_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10928-014-9349-1","volume":"41","author":"L Fronton","year":"2014","unstructured":"Fronton, L., Pilari, S. & Huisinga, W. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J. Pharmacokinet. Pharmacodyn. 41, 87\u2013107 (2014).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"33160_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10928-014-9402-0","volume":"42","author":"A Sepp","year":"2015","unstructured":"Sepp, A., Berges, A., Sanderson, A. & Meno-Tetang, G. Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. J. Pharmacokinet. Pharmacodyn. 42, 97\u2013109 (2015).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"33160_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","volume":"34","author":"A Garg","year":"2007","unstructured":"Garg, A. & Balthasar, J. P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J. Pharmacokinet. Pharmacodyn. 34, 687\u2013709 (2007).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"33160_CR10","first-page":"296","volume":"50","author":"P Kletting","year":"2009","unstructured":"Kletting, P., Bunjes, D., Reske, S. N. & Glatting, G. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 50, 296\u2013302 (2009).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR11","first-page":"484","volume":"51","author":"P Kletting","year":"2010","unstructured":"Kletting, P. et al. Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 51, 484\u2013491 (2010).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1088\/0031-9155\/24\/1\/017","volume":"24","author":"JS Fleming","year":"1979","unstructured":"Fleming, J. S. A technique for the absolute measurement of activity using a gamma camera and computer. Phys. Med. Biol. 24, 176\u2013180 (1979).","journal-title":"Phys. Med. Biol."},{"key":"33160_CR13","first-page":"772","volume":"42","author":"AJ Da Silva","year":"2001","unstructured":"Da Silva, A. J. et al. Absolute quantification of regional myocardial uptake of 99mTc-sestamibi with SPECT: experimental validation in a porcine model. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 42, 772\u2013779 (2001).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"issue":"Suppl 1","key":"33160_CR14","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1007\/s00259-011-1770-8","volume":"38","author":"P Ritt","year":"2011","unstructured":"Ritt, P., Vija, H., Hornegger, J. & Kuwert, T. Absolute quantification in SPECT. Eur. J. Nucl. Med. Mol. Imaging 38(Suppl 1), S69\u201377 (2011).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"33160_CR15","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1088\/0031-9155\/53\/17\/009","volume":"53","author":"S Shcherbinin","year":"2008","unstructured":"Shcherbinin, S., Celler, A., Belhocine, T., Vanderwerf, R. & Driedger, A. Accuracy of quantitative reconstructions in SPECT\/CT imaging. Phys. Med. Biol. 53, 4595\u20134604 (2008).","journal-title":"Phys. Med. Biol."},{"key":"33160_CR16","first-page":"921","volume":"51","author":"J Zeintl","year":"2010","unstructured":"Zeintl, J., Vija, A. H., Yahil, A., Hornegger, J. & Kuwert, T. Quantitative accuracy of clinical 99mTc SPECT\/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 51, 921\u2013928 (2010).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR17","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1088\/0031-9155\/57\/6\/1641","volume":"57","author":"JJ Grudzinski","year":"2012","unstructured":"Grudzinski, J. J. et al. Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT. Phys. Med. Biol. 57, 1641\u20131657 (2012).","journal-title":"Phys. Med. Biol."},{"key":"33160_CR18","first-page":"934","volume":"52","author":"M Tian","year":"2011","unstructured":"Tian, M. et al. Whole-body biodistribution kinetics, metabolism, and radiation dosimetry estimates of 18F-PEG6-IPQA in nonhuman primates. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 52, 934\u2013941 (2011).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/cbr.2008.0530","volume":"24","author":"M Nickel","year":"2009","unstructured":"Nickel, M. et al. Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data. Cancer Biother. Radiopharm. 24, 111\u2013122 (2009).","journal-title":"Cancer Biother. Radiopharm."},{"key":"33160_CR20","unstructured":"Fink-Bennett, D. M. & Thomas, K. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J. Nucl. Med. Technol. 31, 61\u201368; quiz 69\u201370 (2003)."},{"key":"33160_CR21","first-page":"529","volume":"56","author":"L Ferrer","year":"2012","unstructured":"Ferrer, L. et al. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. Q. J. Nucl. Med. Mol. Imaging Off. Publ. Ital. Assoc. Nucl. Med. AIMN Int. Assoc. Radiopharmacol. IAR Sect. Soc. Of 56, 529\u2013537 (2012).","journal-title":"Q. J. Nucl. Med. Mol. Imaging Off. Publ. Ital. Assoc. Nucl. Med. AIMN Int. Assoc. Radiopharmacol. IAR Sect. Soc. Of"},{"key":"33160_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/00003495-200262010-00008","volume":"62","author":"K McKeage","year":"2002","unstructured":"McKeage, K. & Perry, C. M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209\u2013243 (2002).","journal-title":"Drugs"},{"key":"33160_CR23","first-page":"141","volume":"47","author":"AK Gupta","year":"2003","unstructured":"Gupta, A. K., Lad, V. J. & Koshy, A. A. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies. Acta Virol. 47, 141\u2013145 (2003).","journal-title":"Acta Virol."},{"key":"33160_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1040-8428(01)00107-X","volume":"39","author":"GA Wiseman","year":"2001","unstructured":"Wiseman, G. A. et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. Crit. Rev. Oncol. Hematol. 39, 181\u2013194 (2001).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"33160_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hep.510230104","volume":"23","author":"J Villeneuve","year":"1996","unstructured":"Villeneuve, J. et al. The hepatic microcirculation in the isolated perfused human liver. Hepatology 23, 24\u201331 (1996).","journal-title":"Hepatology"},{"key":"33160_CR26","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/2031352a0","volume":"203","author":"FW Brambell","year":"1964","unstructured":"Brambell, F. W., Hemmings, W. A. & Morris, I. G. A Theoretical Model of Gamma-Globulin Catabolism. Nature 203, 1352\u20131354 (1964).","journal-title":"Nature"},{"key":"33160_CR27","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1084\/jem.183.4.1587","volume":"183","author":"RP Junghans","year":"1996","unstructured":"Junghans, R. P. & Waldmann, T. A. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J. Exp. Med. 183, 1587\u20131602 (1996).","journal-title":"J. Exp. Med."},{"key":"33160_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1349-7006.2005.00120.x","volume":"96","author":"T Watanabe","year":"2005","unstructured":"Watanabe, T. et al. Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 96, 903\u2013910 (2005).","journal-title":"Cancer Sci."},{"key":"33160_CR29","doi-asserted-by":"crossref","unstructured":"Meibohm, B. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. (John Wiley & Sons, 2006).","DOI":"10.1002\/9783527609628"},{"key":"33160_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s00259-011-2040-5","volume":"39","author":"C Arrichiello","year":"2012","unstructured":"Arrichiello, C. et al. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan. Eur. J. Nucl. Med. Mol. Imaging 39, 956\u2013966 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"33160_CR31","first-page":"1812","volume":"46","author":"PS Conti","year":"2005","unstructured":"Conti, P. S. et al. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 46, 1812\u20131818 (2005).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR32","first-page":"644","volume":"50","author":"DR Fisher","year":"2009","unstructured":"Fisher, D. R., Shen, S. & Meredith, R. F. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 50, 644\u2013652 (2009).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR33","first-page":"1974","volume":"51","author":"D Minarik","year":"2010","unstructured":"Minarik, D. et al. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 51, 1974\u20131978 (2010).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR34","first-page":"1871","volume":"48","author":"M Cremonesi","year":"2007","unstructured":"Cremonesi, M. et al. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 48, 1871\u20131879 (2007).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"33160_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00259-011-2008-5","volume":"39","author":"SNF Rizvi","year":"2012","unstructured":"Rizvi, S. N. F. et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin\u2019s lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur. J. Nucl. Med. Mol. Imaging 39, 512\u2013520 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"33160_CR36","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","volume":"31","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser, F. et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31, 1977\u20131983 (2013).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"19","key":"33160_CR37","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"Mira Tout","year":"2017","unstructured":"Tout, M. et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a LYSA study. Blood, https:\/\/doi.org\/10.1182\/blood-2016-10-744292 (2017).","journal-title":"Blood"},{"key":"33160_CR38","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.18632\/oncotarget.4672","volume":"6","author":"CW Menke-van der Houven van Oordt","year":"2015","unstructured":"Menke-van der Houven van Oordt, C. W. et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget 6, 30384\u201330393 (2015).","journal-title":"Oncotarget"},{"key":"33160_CR39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11307-014-0810-8","volume":"17","author":"A Natarajan","year":"2015","unstructured":"Natarajan, A. & Gambhir, S. S. Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography. Mol. Imaging Biol. MIB Off. Publ. Acad. Mol. Imaging 17, 539\u2013547 (2015).","journal-title":"Mol. Imaging Biol. MIB Off. Publ. Acad. Mol. Imaging"},{"key":"33160_CR40","doi-asserted-by":"publisher","first-page":"e111113","DOI":"10.1371\/journal.pone.0111113","volume":"9","author":"V Singh","year":"2014","unstructured":"Singh, V. et al. Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro. PloS One 9, e111113 (2014).","journal-title":"PloS One"},{"key":"33160_CR41","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-17-0855","volume":"23","author":"KA Zettlitz","year":"2017","unstructured":"Zettlitz, K. A. et al. ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo. Clin. Cancer Res. 23, 7242\u20137252 (2017).","journal-title":"Clin. Cancer Res."},{"key":"33160_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrs.2015.07.003","volume":"99","author":"AT Vaughan","year":"2015","unstructured":"Vaughan, A. T., Cragg, M. S. & Beers, S. A. Antibody modulation: Limiting the efficacy of therapeutic antibodies. Pharmacol. Res. 99, 269\u2013275 (2015).","journal-title":"Pharmacol. Res."},{"key":"33160_CR43","first-page":"1245","volume":"43","author":"S Shen","year":"2002","unstructured":"Shen, S. et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 43, 1245\u20131253 (2002).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33160-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:16:18Z","timestamp":1671617778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33160-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["33160"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-33160-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]},"assertion":[{"value":"28 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14860"}}